Technology Bundle ID
TAB-1995

Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders

Linked ID
E-138-2008-0
Lead Inventors
Alan Remaley (NHLBI)
Co-Inventors
Marcelo Amar (NHLBI)
Development Stages
Development Status
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
ICs
This invention is directed to use of certain peptide analogs comprising multiple amphipathic helical domains that are able to promote cellular lipid efflux and stimulate lipoprotein lipase activity. As a result, administration of invention peptides lead to reduced incidences of hypertriglyceridemia without inducing toxicity. Existing peptides that stimulate efflux of lipids from cells exhibit unacceptably high toxicity. Invention peptides are superior to existing peptides and can also be used to treat or prevent a vast range of vascular diseases, and their dyslipidemic precursors. Exemplary vascular diseases and conditions that could benefit from treatment with the invention peptides include: dyslipidemia, hyperlipidemia, hypercholesterolemia, HDL deficiency, coronary heart disease, atherosclerosis, and thrombic stroke.
Commercial Applications
  • Treatment of dyslipidemic and vascular disorders
  • Method of identifying therapeutic non-cytotoxic peptides
Competitive Advantages
  • Specific control of lipid efflux and transport
  • Transient hypertriglyceridemia with no reported toxicity

Request More Info

Licensing Contact: